Esophageal cancer

Should gender be considered as an influential factor for patient safety in drug treatment?

Fengxia Liu, Helin Feng, Sumin Guo, Yuhan Chen, Qingyi Liu, Feng Wu, Weikuan Gu, Baoen Shan

Research output: Contribution to journalReview article

Abstract

Aim. Analyze the gender difference of esophageal cancer patients in response to drug treatment. Methods. All publications on clinical trials were collected from PubMed, Scopus, and PMC. Each publication was examined to determine whether the publication is a clinical trial and whether data on gender difference were reported. Results. Selected from a total of 191 publications, data from 7 trials with a total of 2041 patients were evaluated for gender differences. These clinical trials involve different drugs and disease phenotype. A significant difference was obtained between male and female groups from Student’s t-test. There is no conclusive result on age, ethnicity, tumor size, and drug influence. Conclusions. Gender difference in response to treatment potentially most likely exists in esophageal cancer patients, regardless of age, race, and drugs.

Original languageEnglish (US)
Article number6340567
JournalJournal of Oncology
Volume2019
DOIs
StatePublished - Jan 1 2019

Fingerprint

Patient Safety
Esophageal Neoplasms
Publications
Clinical Trials
Pharmaceutical Preparations
Licensure
Therapeutics
PubMed
Reproduction
Students
Phenotype
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Esophageal cancer : Should gender be considered as an influential factor for patient safety in drug treatment? / Liu, Fengxia; Feng, Helin; Guo, Sumin; Chen, Yuhan; Liu, Qingyi; Wu, Feng; Gu, Weikuan; Shan, Baoen.

In: Journal of Oncology, Vol. 2019, 6340567, 01.01.2019.

Research output: Contribution to journalReview article

Liu, Fengxia ; Feng, Helin ; Guo, Sumin ; Chen, Yuhan ; Liu, Qingyi ; Wu, Feng ; Gu, Weikuan ; Shan, Baoen. / Esophageal cancer : Should gender be considered as an influential factor for patient safety in drug treatment?. In: Journal of Oncology. 2019 ; Vol. 2019.
@article{24146422d8234c50a0ccaaef681210f6,
title = "Esophageal cancer: Should gender be considered as an influential factor for patient safety in drug treatment?",
abstract = "Aim. Analyze the gender difference of esophageal cancer patients in response to drug treatment. Methods. All publications on clinical trials were collected from PubMed, Scopus, and PMC. Each publication was examined to determine whether the publication is a clinical trial and whether data on gender difference were reported. Results. Selected from a total of 191 publications, data from 7 trials with a total of 2041 patients were evaluated for gender differences. These clinical trials involve different drugs and disease phenotype. A significant difference was obtained between male and female groups from Student’s t-test. There is no conclusive result on age, ethnicity, tumor size, and drug influence. Conclusions. Gender difference in response to treatment potentially most likely exists in esophageal cancer patients, regardless of age, race, and drugs.",
author = "Fengxia Liu and Helin Feng and Sumin Guo and Yuhan Chen and Qingyi Liu and Feng Wu and Weikuan Gu and Baoen Shan",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/6340567",
language = "English (US)",
volume = "2019",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Esophageal cancer

T2 - Should gender be considered as an influential factor for patient safety in drug treatment?

AU - Liu, Fengxia

AU - Feng, Helin

AU - Guo, Sumin

AU - Chen, Yuhan

AU - Liu, Qingyi

AU - Wu, Feng

AU - Gu, Weikuan

AU - Shan, Baoen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim. Analyze the gender difference of esophageal cancer patients in response to drug treatment. Methods. All publications on clinical trials were collected from PubMed, Scopus, and PMC. Each publication was examined to determine whether the publication is a clinical trial and whether data on gender difference were reported. Results. Selected from a total of 191 publications, data from 7 trials with a total of 2041 patients were evaluated for gender differences. These clinical trials involve different drugs and disease phenotype. A significant difference was obtained between male and female groups from Student’s t-test. There is no conclusive result on age, ethnicity, tumor size, and drug influence. Conclusions. Gender difference in response to treatment potentially most likely exists in esophageal cancer patients, regardless of age, race, and drugs.

AB - Aim. Analyze the gender difference of esophageal cancer patients in response to drug treatment. Methods. All publications on clinical trials were collected from PubMed, Scopus, and PMC. Each publication was examined to determine whether the publication is a clinical trial and whether data on gender difference were reported. Results. Selected from a total of 191 publications, data from 7 trials with a total of 2041 patients were evaluated for gender differences. These clinical trials involve different drugs and disease phenotype. A significant difference was obtained between male and female groups from Student’s t-test. There is no conclusive result on age, ethnicity, tumor size, and drug influence. Conclusions. Gender difference in response to treatment potentially most likely exists in esophageal cancer patients, regardless of age, race, and drugs.

UR - http://www.scopus.com/inward/record.url?scp=85071302213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071302213&partnerID=8YFLogxK

U2 - 10.1155/2019/6340567

DO - 10.1155/2019/6340567

M3 - Review article

VL - 2019

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 6340567

ER -